A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic-pharmacodynamic profile of the heat shock protein 90 (Hsp90) inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. METHODS: This was a single institution, phase I, dose-escalation...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Rajan, Arun, Kelly, Ronan J., Trepel, Jane B., Kim, Yeong Sang, Alarcon, Sylvia V., Kummar, Shivaani, Gutierrez, Martin, Crandon, Sonja, Zein, Wadih M., Jain, Lokesh, Mannargudi, Baskar, Figg, William D., Houk, Brett E., Shnaidman, Michael, Brega, Nicoletta, Giaccone, Giuseppe
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2011
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3207004/
https://ncbi.nlm.nih.gov/pubmed/21908572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0821
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla